Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mitiglinide (KAD-1229) is an insulinotropic agent that is an ATP-sensitive K + (K ATP ) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K ATP channel). Mitiglinide is able to be used for the research of type 2 diabetes [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Mitiglinide (KAD-1229) is an insulinotropic agent that is an ATP-sensitive K + (K ATP ) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K ATP channel). Mitiglinide is able to be used for the research of type 2 diabetes [1] [2]. |
In vitro | In COS-1 cells, Mitiglinide inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC 50 of 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (over 10 μM) [1]. |
In vivo | Mitiglinide, administered orally at doses ranging from 1 to 3 mg/kg, effectively reduces the postprandial elevation in plasma glucose levels and decreases the glucose area under the curve (AUCglucose) for up to five hours following a meal [2]. This dose-dependent suppression of AUCglucose was observed in an animal model involving pregnant Wistar rats aged 12 weeks, with dosages administered at 0.3 mg/kg, 1 mg/kg, and 3 mg/kg [2]. |
Molecular Weight | 315.41 |
Formula | C19H25NO3 |
CAS No. | 145375-43-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mitiglinide 145375-43-5 inhibitor inhibit